TherOx Inc., an Irvine company that is developing treatments for heart attack patients, said Wednesday it has closed a $30 million round of financing.
DAG Ventures of Palo Alto led the round. Kleiner Perkins Caufield & Byers, New Science Ventures, Integral Capital Partners, Aperture Venture Partners and Cross Creek Capital also participated.
TherOx plans to use the money to take its SuperSaturated Oxygen Therapy product through the Food and Drug Administration regulatory approval process and to launch it upon regulatory clearance, said Shelley Thunen, TherOx’s chief financial officer.
SuperSaturated Oxygen Therapy involves creating and delivering superoxygenated arterial blood to salvage heart muscle in acute heart attack patients.
